Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
about
Adding pharmacogenomics to the development of new marine-derived anticancer agentsAdvanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedinTrabectedin for Soft Tissue Sarcoma: Current Status and Future PerspectivesThe value of trabectedin in the treatment of soft tissue sarcomaEfficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic reviewTrabectedin for advanced soft tissue sarcomas: optimizing useUpdate on clinical research and state of the art management of patients with advanced sarcomas and GISTMajor clinical research advances in gynecologic cancer in 2015Trabectedin in soft tissue sarcomasManagement Strategies in Advanced Uterine Leiomyosarcoma: Focus on TrabectedinPazopanib in the treatment of soft tissue sarcomaEcteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cellsThe evolution of systemic therapy in sarcoma.Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds.Trabectedin and its potential in the treatment of soft tissue sarcoma.Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.Trabectedin for the management of soft-tissue sarcoma.Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.Cost-effectiveness of pazopanib in advanced soft tissue sarcoma in the United kingdom.Role of trabectedin in the treatment of soft tissue sarcomaMarine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cellsPneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case seriesTrabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma.Trabectedin: safety and efficacy in the treatment of advanced sarcomaCase Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic LeiomyosarcomaClinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.Recent advances in understanding and managing leiomyosarcomasGrowth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
P2860
Q25254985-F182A57B-1259-46B1-9707-0EDB2946C778Q26738346-C6A15718-1ACE-4241-8BE6-EF98815AF21CQ26745502-01B077DD-5937-4466-B977-2C6F4233336FQ26772855-B0D07D12-9061-40A8-AA20-EE7A8EEF6B26Q26822530-0D64D45A-C5A2-46A5-AB5F-1CBA0C9AE1D7Q26860365-17CDEFE1-54A4-48E9-BA08-76B6AB633E8FQ28073290-27803634-7DD6-466F-BBA2-C8E4C27540DAQ28077183-F2C56012-C69B-4CCA-B910-E2E3D9576E83Q28085505-1CF9EF9A-0C3B-4211-A0DC-2AFBC8DB84B2Q28087771-B5D09EB8-7775-497E-AC0D-63BB49A1E4C2Q28269229-DC300EA6-2351-4423-8B61-46FAD3780731Q28307320-45F17BAC-F39E-4FE3-92A5-ED996042CA96Q33274710-1CC57C2F-A6C1-4C74-9605-A73C2808C837Q33359943-18755603-219A-4A38-BEA4-C4A7D8766712Q33380903-C11F3F3F-26A9-47B9-BC1C-CC908C97675CQ33381641-E8CC3E8B-07AC-4137-BDF7-7DB7C13AA297Q33384836-CF92AACE-A22D-4E68-90F4-80D39883E5B5Q33392364-3488E22F-6C7B-4BE4-8150-0A8DDD4D7779Q33397403-9B1E1E62-21A3-4511-93FF-4A4CB71F0569Q33400959-DB8882A8-AC8D-4F24-9E68-62CC8411138BQ33419792-2C845AA6-1D7E-4826-9510-E8205E9B90DDQ33426789-4AEC59AD-2FC6-4921-B8AA-411F2CFC97E2Q33438485-FE9C38DE-BE7B-4A52-8D5C-DC28E359937CQ33561602-65F9BC60-F20A-4A2F-8EEB-CF466141AB0EQ33850011-2908B94A-DA2D-4A35-96D9-1EFC4B8A4964Q33916011-D0B4EED1-A5CB-4945-945D-3EFB3EAA6366Q34166391-BB040876-C33C-4187-B47E-C3C8C5C1D9A1Q34314062-0BDAEDA4-45F1-4E28-B146-E80C9EBA1489Q34356540-32DD5B97-0E61-45AB-901A-F1816D5ED97BQ34578850-293A05F9-1423-446F-883B-DB90037D5430Q34580659-94323E95-09D5-4FCB-85D3-9EB0F81A0160Q34581388-72B7D4DE-4E25-45E1-93F1-06E7D330A876Q34622323-06453D64-5ACF-4908-91DE-0F25D59A9BCEQ34628607-B745690A-D1FF-4230-A75F-9C067D9F5A81Q34629491-C2CC9377-3185-4D90-8B8D-EAF78A32ED2EQ34647970-FCBB9CB5-722B-4F16-9ABE-3CDF8B9B9FF8Q34659530-6831EE26-E323-458B-BFE5-DE7BFDE356C9Q34670825-8F25444E-3A1F-4E65-B741-ED9DE3DB8476Q34736667-27BF79E8-E902-4A3B-BB56-0AF317677C42Q35058617-30A23CBE-DA31-40D7-BB59-ACA2A0D84CBD
P2860
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Phase II study of ET-743 in ad ...... and bone sarcoma group trial.
@ast
Phase II study of ET-743 in ad ...... and bone sarcoma group trial.
@en
Phase II study of ET-743 in ad ...... search and Treatment of Cancer
@nl
type
label
Phase II study of ET-743 in ad ...... and bone sarcoma group trial.
@ast
Phase II study of ET-743 in ad ...... and bone sarcoma group trial.
@en
Phase II study of ET-743 in ad ...... search and Treatment of Cancer
@nl
prefLabel
Phase II study of ET-743 in ad ...... and bone sarcoma group trial.
@ast
Phase II study of ET-743 in ad ...... and bone sarcoma group trial.
@en
Phase II study of ET-743 in ad ...... search and Treatment of Cancer
@nl
P2093
P50
P356
P1476
Phase II study of ET-743 in ad ...... and bone sarcoma group trial.
@en
P2093
A Van Oosterom
E Di Paola
M Van Glabbeke
O S Nielsen
S Bonvalot
S Rodenhuis
P304
P356
10.1200/JCO.2005.01.180
P407
P577
2005-01-01T00:00:00Z